The Bhagwan Mahaveer Cancer Hospital and Research Centre (BMCHRC) is a not-for-profit super specialty cancer hospital managed by the in K G Kothari Memorial Trust in Jaipur, Rajasthan, India. It was established to provide comprehensive cancer care to the patients at an affordable cost, irrespective of economic consideration. The hospital was commissioned in 1996 by Navrattan Kothari and became operational in 1997. BMCHRC is a National Accreditation Board for Hospitals & Healthcare Providers (NABH) accredited institution following international protocol for cancer treatment.
Background: Access to palliative care is still limited in India with Rajasthan and this is accompanied by a lack of awareness and trained personnel. Frontline workers like ASHAs and ANMs can help to improve early identification and referral of patients in need of palliative care. To assess effectiveness of palliative care training of ASHAs and ANMs and its effect on the pattern of referrals to patients in Jodhpur. Methods: A quasi-experimental study was carried out in selected 21 Urban Primary Health Centres in the period from before (Sept-2024 to Jun-2025). The participants went through a two-day structured training programme. Knowledge was evaluated by a validated 18-item questionnaire in pre- and post-tests and referrals were followed for 6 months. Data were analysed with paired t-test and descriptive statistics. Results: Significant improvement of knowledge scores was noted post training (P<0.05) with similar improvement among ASHAs and ANMs. A total of patients were identified and referred with a steady increase in referrals over time. Field exposure through home visits increased use of referral activity. Conclusions: Structured training has been effective in improving knowledge and referral practices. Integrating trained frontline workers with supportive supervision and referral systems in community-based palliative care in resource limited settings.
Platinum-based chemotherapy remains the standard first-line treatment for extensive disease small cell lung carcinoma (ED-SCLC). However, therapeutic options in the second-line setting, particularly after disease progression on etoposide-cisplatin regimens, are limited. The combination of capecitabine and temozolomide (CAP-TEM) has shown activity in various neuroendocrine tumors, but evidence in ED-SCLC remains scarce. This real-world study aimed to evaluate the efficacy and safety of the CAP-TEM regimen in platinum-refractory ED-SCLC patients in a real-world tertiary care setting in Northern India. This was a prospective interventional study conducted at Bhagwan Mahaveer Cancer Hospital and Research Centre, Jaipur, between June 2023 and December 2024. A total of 36 histopathologically confirmed ED-SCLC patients, who progressed after first-line etoposide-cisplatin chemotherapy and met predefined inclusion criteria, were enrolled. Patients received oral capecitabine (625 mg/m2 twice daily, days 1–14) and temozolomide (150 mg/m2 once daily, days 10–14) every 28 days for up to 6 cycles. Tumor response was assessed radiologically every 3 cycles. Safety assessments were based on CTCAE v5.0 criteria. Survival analysis was performed using Kaplan-Meier methods. Among 36 evaluable patients, the disease control rate (DCR) was 69.4
234 Background: Surgical outcomes in head and neck cancer (HNC) are influenced by patient-related factors (nutritional status, comorbidities), disease-related factors (tumor stage and type), and perioperative variables (surgical duration, anesthetic management). Despite the high global incidence of HNC, comprehensive prospective data evaluating perioperative predictors of outcomes remain limited, highlighting the need for systematic investigation in this area. Methods: This prospective, single-center observational study was conducted following Institutional Ethics Committee approval and prospective CTRI registration (CTRI/2025/10/096289; registered on 22/10/2025). Patient enrollment began on 05/11/2025. Adults undergoing major HNC surgery were included. Data collected encompassed demographics, comorbidities, medications, nutritional status, and detailed intraoperative anesthetic variables, including fluid therapy, vasopressor use, duration of hypotension, and blood loss. The primary outcome was a composite of 30-day major complications (Clavien–Dindo grade ≥III) and mortality. The planned sample size is 1,540 participants, with a recruitment period of two years and an additional one-year follow-up. Interim analyses were performed on the initial cohort. Results: In the first 100 enrolled patients (mean age 52 years; 74% male), comorbidity burden was substantial (ASA ≥III: 20%; median Caprini score: 5). Major complications or death within 30 days occurred in 15% of patients. Increased intraoperative blood loss emerged as the strongest independent predictor of adverse outcomes, while higher Caprini scores showed a trend toward increased risk. These findings highlight blood loss as a key modifiable perioperative factor and support the utility of the Caprini score for preoperative risk stratification in HNC surgery. Conclusion: Preliminary results from this ongoing study demonstrate a high prevalence of nutritional deficits and intraoperative hemodynamic instability in patients undergoing major HNC surgery. These perioperative factors represent potential targets for intervention to improve early postoperative outcomes. Continued recruitment and long-term follow-up are underway to further clarify predictors of short- and long-term survival. Conflict of Interest: None declared. Funding: Investigator-initiated study with no external funding. Characteristic All patients (N=100) No major comp. (n=85) Major comp. (n=15) p-value Age (years), mean ± SD 52.4 ± 11.9 51.6 ± 11.7 56.9 ± 12.1 0.098 BMI (kg/m²), mean ± SD 24.1 ± 4.5 24.3 ± 4.6 23.2 ± 3.5 0.386 ASA grade ≥3 20 (20.0) 14 (16.5) 6 (40.0) 0.045 Caprini score, median (IQR) 5 (5–6) 5 (5–6) 6 (5–7) 0.029 Surgery duration (min), mean ± SD 342 ± 82 334 ± 78 386 ± 96 0.023 Blood loss (mL) median (IQR) 700 (500–900) 650 (400–850) 900 (700–1200) 0.005
BACKGROUND:While probiotics show promise in reducing chemoradiotherapy side effects like oral mucositis in head and neck cancer patients, robust clinical evidence of their consistent effectiveness is still needed. The objectives of this study were to compare the incidence and severity of oral mucositis, dysphagia, and compliance of radiotherapy treatment between the study arm (oral probiotics, along with concurrent chemoradiotherapy) and the control arm (concurrent chemoradiotherapy alone) in patients of locally advanced carcinoma oropharynx. MATERIALS AND METHODS:A total of 70 patients of carcinoma of the oropharynx were randomized to the probiotics arm (study arm, n = 35) and the non-probiotics arm (control arm, n = 35). All patients received radiotherapy to a total dose of 70 Gy in 35 fractions, along with concurrent weekly cisplatin chemotherapy. Patients in the probiotics arm were given 65 ml of probiotic milk beverage (Yakult) containing 6.5 billion colony-forming units Lactobacillus casei Shirota strain to drink once a day for 7 weeks during chemoradiotherapy treatment. RESULTS:Incidence of severe mucositis, dysphagia, and significant weight loss was significantly lower in the probiotics arm compared to the control arm. Patients in the probiotics arm experienced significantly less grade 3 oral mucositis (four patients, 11.43%) and grade 3 dysphagia (six patients, 17.14%) compared to patients in the control arm (12 patients, 34.29% and 13 patients, 37.14%, respectively; P < 0.001). Compliance was not statistically different in both the arms. CONCLUSION:In this randomized clinical trial of carcinoma oropharynx patients, probiotics reduced the concurrent chemoradiotherapy-induced severe oral mucositis and dysphagia.